Mould illness — more precisely called Chronic Inflammatory Response Syndrome (CIRS) when it involves the innate immune system — is estimated to affect around 25% of the population at some level of susceptibility. This is because roughly one in four people carry HLA gene variants that impair the body's ability to recognise and clear mycotoxins — the toxic compounds produced by certain moulds in water-damaged buildings.
In a person without these variants, mycotoxins are bound in the gut and cleared through normal detoxification pathways. In a susceptible individual, they are not. The biotoxins recirculate. The innate immune system keeps triggering. Inflammatory cytokines — including C4a, TGF-β1, and MMP-9 — remain chronically elevated. The result is a multi-system, multi-symptom condition that can affect energy, cognition, mood, immunity, gut function, and hormonal regulation simultaneously.
The investigation that could find this simply isn't offered in standard care — which is why most people with mould illness have already seen multiple practitioners before they get answers.
Standard GP testing does not include any of these markers. A standard blood panel does not include urinary mycotoxin analysis. A normal chest X-ray does not rule out the immunological consequences of mould exposure.